Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma-Reference-Cited by-同舟云学术

Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

Published:2015-09-14 Issue:21 Volume:35 Page:2687-2697
ISSN:0950-9232
Container-title:Oncogene
language:en
Short-container-title:Oncogene

Author:

Zhou L,Liu X-D,Sun M,Zhang X,German P,Bai S,Ding Z,Tannir N,Wood C G,Matin S F,Karam J A,Tamboli P,Sircar K,Rao P,Rankin E B,Laird D A,Hoang A G,Walker C L,Giaccia A J,Jonasch E

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Molecular Biology

Link

http://www.nature.com/articles/onc2015343.pdf

Reference48 articles.

1. Thoenes W, Storkel S, Rumpelt HJ . Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract 1986; 181: 125–143.

2. Kanesvaran R, Tan MH . Targeted therapy for renal cell carcinoma: The next lap. J Carcinog 2014; 13: 3.

3. Domblides C, Gross-Goupil M, Quivy A, Ravaud A . Emerging antiangiogenics for renal cancer. Expert Opin Emerg Drugs 2013; 18: 495–511.

4. Griffioen AW, Mans LA, de Graaf AM, Nowak-Sliwinska P, de Hoog CL, de Jong TA et al. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res 2012; 18: 3961–3971.

5. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010; 70: 1063–1071.

Cited by 324 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dosage by design – 3D printing individualized cabozantinib tablets with immediate release;European Journal of Pharmaceutics and Biopharmaceutics;2024-09

2. Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer;Investigational New Drugs;2024-08-21

3. E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response Network;Cancer Research Communications;2024-07-01

4. Milestones in tumor vascularization and its therapeutic targeting;Nature Cancer;2024-06-25

5. The efficacy and safety of cabozantinib in patients with metastatic or advanced renal cell carcinoma: a systematic review and meta-analysis;Baylor University Medical Center Proceedings;2024-06-17